Lilly's Baricitinib Wins US FDA Panel Thumbs Up For One Of Two Doses

 
• By Sue Sutter

Despite concerns about small size of safety database, Arthritis Advisory Committee endorses 2 mg dose; panel recommends against approval of 4 mg dose due to stronger thrombosis signal in clinical trials, brushing back Lilly's attempt to position the higher dose as having a positive benefit-risk profile in patients with more refractory disease.

FDA Advisory Committee Feature image

More from US FDA Performance Tracker

More from Regulatory Trackers